Table 2.
Comparison of GBS-C+ and GBS-C−.
| COVID+ n = 10 |
COVID− n = 10 |
Value*,† | P | |
|---|---|---|---|---|
| M:F | 6:4 | 4:5 | 0.202* | .502 |
| Age | 67.8 ± 9.8 | 61.30 ± 11.05 | 1.064† | .289 |
| Sum MRC score on admission | 37.8 ± 17.2 | 45.6 ± 12.7 | −1.21† | .022 |
| Hughes score on admission | ||||
| 1 | 0 | 1 | 6.800* | .031 |
| 2 | 1 | 4 | ||
| 3 | 4 | 0 | ||
| 4 | 5 | 5 | ||
| Facial involvement | 5/10 | 2/10 | 2.359* | .307 |
| CSF albumin (mg/dL) | 52 ± 37.48 | 60.1 ± 37.21 | -0.61† | .540 |
| Lymphocytes (count/mm3) | 1491 ± 616 | 2069 ± 935 | −1.2† | .025 |
| C-reactive protein (mg/dL) | 3.92 ± 5.8 | 2.2 ± 3.4 | −1.024*,* | .061 |
| Antiganglioside antibodies positivity | 0/10 | 2/10 | ||
| Clinical form of GBS | ||||
| AIDP | 7 | 6 | ||
| AMAN/AMSAN | 2 | 3 | ||
| Miller-Fisher syndrome | 1 | 1 | ||
| Plasma exchange after immunoglobulin (IVIg) failure | 0 | 1 | ||
| Unfavorable prognosis (6–14 mo): unable to walk unassisted | 2/10 | 2/10 | ||